Gennex Laboratories Limited has formally distributed the notice for its Extraordinary General Meeting (EGM) to stock exchanges, following the board's earlier approval on April 16, 2026. The company sent the official EGM notice on April 20, 2026, to BSE Limited, The Ahmedabad Stock Exchange Limited, and The Calcutta Stock Exchange Limited.

EGM Details and Formal Notice Distribution

The EGM notice has been officially communicated to multiple stock exchanges where the company's shares are listed. The formal distribution was completed on April 20, 2026, in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

Director Regularization Process

The EGM will address the regularization of Ms. Khushbu Kachhawa (DIN: 10872432) as a Non-Executive Independent Woman Director. She was initially appointed as an Additional Director on February 14, 2026, following the resignation of Ms. Shilpa Bung (DIN: 08257931) due to personal reasons and professional pre-occupations. The appointment aims to fill the casual vacancy of Woman Director and strengthen board diversity.

E-Voting Schedule and Administrative Arrangements

The company has updated the e-voting timeline and confirmed administrative arrangements for the EGM. NSDL will serve as the authorized agency for facilitating e-voting, while Ms. Sweety Kapoor, a Practicing Company Secretary from Kolkata, has been appointed as the scrutinizer.

Stock Exchange Communication and Compliance

The EGM notice has been sent to all relevant stock exchanges with proper script codes for identification. The communication ensures compliance with regulatory requirements and provides shareholders with necessary information for participation.

The notice is available on the company's website and will be accessible through stock exchange platforms and NSDL's e-voting portal. Shareholders can participate through video conferencing, with the deemed venue being the company's registered office at Sy. No. 133, IDA Bollaram, Jinnaram Mandal, Medak, Telangana.

Gennex Laboratories Limited has fulfilled its quarterly regulatory obligations by submitting the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Regulatory Submission Details

The pharmaceutical company submitted the compliance certificate to multiple stock exchanges on April 13, 2026. The submission was addressed to three major exchanges where the company's securities are listed:

Certificate Confirmation

R&D Infotech Private Limited, serving as the company's registrar and transfer agent, issued the certificate on April 06, 2026. The certificate confirms several key compliance aspects:

• Securities received from depository participants for dematerialisation during the quarter were properly confirmed to the depositories
• All securities comprised in the certificates have been listed on stock exchanges where previously issued securities are traded
• Security certificates received for dematerialisation were mutilated and cancelled after due verification
• Names of depositories were substituted in the register of members as registered owners within the mandated 15-day period

Company Authorization

The submission was authorized by Dinesh Kumar Kejriwal, Company Secretary (Membership # A/19293), who digitally signed the documents on April 13, 2026. The certificate was signed by Ratan Kumar Mishra on behalf of R&D Infotech Private Limited.

Regulatory Context

This quarterly submission represents standard compliance with SEBI regulations governing depositories and participants. The regulation ensures proper handling and processing of securities during the dematerialisation process, maintaining transparency and investor protection in the securities market.

Gennex Laboratories operates from its office in Hyderabad and maintains manufacturing facilities in Telangana. The company continues to meet its regulatory obligations across multiple stock exchanges where its securities are listed.